Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kaopectate Prop 65

This article was originally published in The Tan Sheet

Executive Summary

San Francisco County Judge approves settlement between Pfizer, Attorney General Bill Lockyer in Prop 65 lawsuit regarding Kaopectateanti-diarrheal. Pfizer, which obtained the drug after acquiring Pharmacia, agrees to reformulate Kaopectate liquid with 80% less lead; caplets have not yet been reformulated. "The faster and more extensively Pharmacia removes lead from Kaopectate, the less it will pay in civil penalties," AG's office states June 26. Center for Environmental Health filed suit in 2001 (1"The Tan Sheet" March 26, 2001, p. 21). State AG joined in November 2001...

You may also be interested in...



Smoking Cessation Patch, Gum Prop 65 Warning Federally Preempted - Court

Requiring a special California Proposition 65 pregnancy warning on OTC nicotine-containing smoking cessation patches and gums would conflict with FDA requirements, a San Francisco state court judge has ruled.

Germany’s OTC Market In 2023: Cough, Cold & Flu and Probiotics Drove Steady Growth

German consumers are “generally willing to accept price increases from OTC manufacturers” when it comes to core categories like cough, cold & flu, finds Sempora, and are increasingly willing to shell out for trending gut health products like probiotics.

FDA Delay Will Not Push Rocket Pharma Off Its Trajectory

The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel